G
George P. Allen
Researcher at New England College
Publications - 8
Citations - 293
George P. Allen is an academic researcher from New England College. The author has contributed to research in topics: Levofloxacin & Moxifloxacin. The author has an hindex of 7, co-authored 8 publications receiving 266 citations. Previous affiliations of George P. Allen include Oregon State University & Detroit Receiving Hospital.
Papers
More filters
Journal ArticleDOI
In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model
TL;DR: A number of novel antimicrobial combinations that may be useful against staphylococci and enterococci are suggested and warrant further investigation for the treatment of refractive infections due to multidrug-resistant gram-positive pathogens.
Journal ArticleDOI
The Role of Servant Leadership and Transformational Leadership in Academic Pharmacy
George P. Allen,W. Mark Moore,Lynette R. Moser,Kathryn K. Neill,Usha Sambamoorthi,Hershey S. Bell +5 more
TL;DR: Servant and transformational leadership have attributes that provide guidance and inspiration through changes and may both be ideal for leaders in academic pharmacy.
Journal ArticleDOI
Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model
George P. Allen,George P. Allen,Glenn W. Kaatz,Glenn W. Kaatz,Glenn W. Kaatz,Michael J. Rybak,Michael J. Rybak,Michael J. Rybak +7 more
TL;DR: It is concluded that the reduced recovery of resistant mutants of S. pneumoniae following moxifloxacin exposure compared to levofloxACin may be due to intrinsic differences between the drugs.
Journal ArticleDOI
Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model
TL;DR: Higher doses of vancomycin (1.5 g every 12 h) and LY333328 may represent potential treatment options for infections caused by GISA strains, and are significantly correlated with the AUC0–24 by multiple stepwise regression analyses.
Journal ArticleDOI
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
TL;DR: Clinical and microbiologic results were comparable to the fluoroquinolone comparators in all trials, and levofloxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and dizziness being the most commonly reported adverse events.